| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $76,204,534 | 17 | 100 |
| Long Daniel D. | SVP, Drug Discovery | 0 | $0 | 5 | $951,331 | $-951,331 |
| Bhatt Elizabeth | President and COO | 0 | $0 | 5 | $1.6M | $-1.6M |
| Shaikhly Samira | Chief People Officer | 0 | $0 | 5 | $2.8M | $-2.8M |
| Third Rock Ventures V, L.P. | 10 percent owner | 0 | $0 | 1 | $7.4M | $-7.4M |
| RA CAPITAL MANAGEMENT, L.P. | 0 | $0 | 1 | $63.45M | $-63.45M |
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM …
Over the last 12 months, insiders at Septerna Inc have bought $0 and sold $76.2M worth of Septerna Inc stock.
On average, over the past 5 years, insiders at Septerna Inc have bought $0 and sold $76.2M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
| 2026-10-15 | Sale | Bhatt Elizabeth | President and COO | 4,000 0.0086% | $37.41 | $149,644 | +10.49% | |
| 2026-09-01 | Sale | Long Daniel D. | SVP, Drug Discovery | 3,333 0.0074% | $37.83 | $126,078 | +2.03% | |
| 2026-08-12 | Sale | Third Rock Ventures V, L.P. | 10 percent owner | 147,200 0.3407% | $50.27 | $7.4M | -19.31% | |
| 2026-08-12 | Sale | RA CAPITAL MANAGEMENT, L.P. | 1.49M 2.9211% | $42.50 | $63.45M | -19.31% | ||
| 2026-08-11 | Sale | Bhatt Elizabeth | President and COO | 25,000 0.0511% | $44.00 | $1.1M | -18.53% | |
| 2026-08-03 | Sale | Long Daniel D. | SVP, Drug Discovery | 3,334 0.0073% | $34.47 | $114,920 | +11.23% | |
| 2026-07-15 | Sale | Bhatt Elizabeth | President and COO | 4,000 0.0089% | $33.99 | $135,974 | +13.08% | |
| 2026-07-01 | Sale | Long Daniel D. | SVP, Drug Discovery | 3,333 0.0073% | $34.36 | $114,528 | +10.23% | |
| 2026-06-29 | Sale | Shaikhly Samira | Chief People Officer | 2,178 0.0049% | $35.18 | $76,622 | +9.73% | |
| 2026-06-22 | Sale | Long Daniel D. | SVP, Drug Discovery | 15,000 0.0339% | $35.51 | $532,582 | +8.81% | |
| 2026-06-12 | Sale | Shaikhly Samira | Chief People Officer | 6,250 0.0135% | $35.08 | $219,224 | +5.06% | |
| 2026-06-01 | Sale | Shaikhly Samira | Chief People Officer | 5,935 0.0127% | $28.93 | $171,683 | +25.18% | |
| 2026-05-26 | Sale | Shaikhly Samira | Chief People Officer | 11,798 0.0264% | $30.06 | $354,656 | +22.06% | |
| 2026-04-15 | Sale | Bhatt Elizabeth | President and COO | 4,000 0.0084% | $24.34 | $97,343 | +38.89% | |
| 2026-03-02 | Sale | Shaikhly Samira | Chief People Officer | 70,453 0.1524% | $28.10 | $1.98M | +19.97% | |
| 2026-02-18 | Sale | Bhatt Elizabeth | President and COO | 4,000 0.0091% | $28.97 | $115,860 | +20.14% | |
| 2025-11-10 | Sale | Long Daniel D. | SVP, Drug Discovery | 3,501 0.0054% | $18.06 | $63,223 | +60.33% |
| Increased Positions | 77 | +92.77% | 5M | +10.75% |
| Decreased Positions | 32 | -38.55% | 4M | -8.39% |
| New Positions | 46 | New | 2M | New |
| Sold Out Positions | 5 | Sold Out | 572,837 | Sold Out |
| Total Postitions | 128 | +54.22% | 46M | +2.36% |